The search for cancer biomarkers is frequently based on comparisons between tumors and adjacent-to-tumor samples. However, even after histological confirmation of been free of cancer cells, these adjacent-to-tumor sam...The search for cancer biomarkers is frequently based on comparisons between tumors and adjacent-to-tumor samples. However, even after histological confirmation of been free of cancer cells, these adjacent-to-tumor samples might harbor molecular alterations which are not sufficient to cause them to look like cancer, but can differentiate these cells from normal cells. When comparing them, potential biomarkers are missed, and mainly the opportunity of finding initial aberrations presents in both tumors and adjacent samples, but not in true normal samples from non-cancer patients, resulting in misinterpretations about the carcinogenic process. Nevertheless, collecting adjacent-to-tumor samples brings trumps to be explored. The addition of samples from non-cancer patients opens an opportunity to increase the finds of the molecular cascade of events in the carcinogenic process. Differences between normal samples and adjacent samples might represent the first steps of the carcinogenic process. Adding samples of non-cancer patients to the analysis of molecular alterations relevant to the carcinogenic process opens a new window of opporttmides to the discovery of cancer biomarkers and molecular targets.展开更多
Neurofibromin 2(NF2)-related schwannomatosis(NF2-SWN)is an autosomal-dominant tumor predisposition syndrome.NF2-SWN patients develop multiple benign tumors of the nervous system,such as schwannomas,particularly bilate...Neurofibromin 2(NF2)-related schwannomatosis(NF2-SWN)is an autosomal-dominant tumor predisposition syndrome.NF2-SWN patients develop multiple benign tumors of the nervous system,such as schwannomas,particularly bilateral vestibular schwannomas,without current effective treatments.1 These tumors are caused by the bi-allelic inactivation of the NF2 gene,which encodes for merlin protein,in a cell of the Schwann cell(SC)lineage.展开更多
基金National Counsel of Technological and Scientific Development and Coordination for Enhancement of Higher Education Personnel for fellowship support
文摘The search for cancer biomarkers is frequently based on comparisons between tumors and adjacent-to-tumor samples. However, even after histological confirmation of been free of cancer cells, these adjacent-to-tumor samples might harbor molecular alterations which are not sufficient to cause them to look like cancer, but can differentiate these cells from normal cells. When comparing them, potential biomarkers are missed, and mainly the opportunity of finding initial aberrations presents in both tumors and adjacent samples, but not in true normal samples from non-cancer patients, resulting in misinterpretations about the carcinogenic process. Nevertheless, collecting adjacent-to-tumor samples brings trumps to be explored. The addition of samples from non-cancer patients opens an opportunity to increase the finds of the molecular cascade of events in the carcinogenic process. Differences between normal samples and adjacent samples might represent the first steps of the carcinogenic process. Adding samples of non-cancer patients to the analysis of molecular alterations relevant to the carcinogenic process opens a new window of opporttmides to the discovery of cancer biomarkers and molecular targets.
基金funded by Chromo22the ISCIII(No.PI20/00215,PI23/00619)(Co-funded by the European Regional Development Fund“A way to make Europe”)+4 种基金AC22/00033,partner of the EJPRDThe EJPRD initiative has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No.825575funded also by FundacióLa Maratóde TV3(No.126/C/2020)the Children's Tumor Foundation(No.CTF-2019-05-005,CTF-2022-05-005)Fundación Proyecto Neurofibromatosis,and the Government of Catalonia(No.SGR-Cat 2021-00967).
文摘Neurofibromin 2(NF2)-related schwannomatosis(NF2-SWN)is an autosomal-dominant tumor predisposition syndrome.NF2-SWN patients develop multiple benign tumors of the nervous system,such as schwannomas,particularly bilateral vestibular schwannomas,without current effective treatments.1 These tumors are caused by the bi-allelic inactivation of the NF2 gene,which encodes for merlin protein,in a cell of the Schwann cell(SC)lineage.
